Treace Medical Concepts (NASDAQ:TMCI) Announces Earnings Results, Beats Estimates By $0.03 EPS

Treace Medical Concepts (NASDAQ:TMCI) released its quarterly earnings results on Friday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03, FiscalAI reports. Treace Medical Concepts had a negative net margin of 27.74% and a negative return on equity of 59.91%. The company had revenue of $47.20 million during the quarter, compared to the consensus estimate of $45.96 million.

Here are the key takeaways from Treace Medical Concepts’ conference call:

• Q1 revenue was $47.2 million, down ~10% year‑over‑year, with a net loss of $18.0 million and an adjusted EBITDA loss of $5.5 million, driven by lower bunion kit volumes and a shift toward lower‑priced products.
• Management reaffirmed full‑year 2026 guidance of $202–$212M in revenue (‑5% to 0% vs. 2025) and expects adjusted EBITDA loss of $4–$6M, while targeting a roughly 50% reduction in cash usage versus 2025.
• Commercial traction is building for the 2025 product launches — about 35% of Lapiplasty surgeons have adopted at least one of the three new bunion systems (up from 25% in Q4), and ~30% of new surgeons who started with those systems have also used Lapiplasty, indicating early pull‑through.
• The product roadmap is expanding — full commercialization of SuperBite and SpeedXM is expected in Q3 and Lapiplasty Lightning later this year, collectively increasing the addressable market by roughly $300M and opening access to higher‑ASP midfoot and hindfoot procedures.
• Management noted persistent macro pressure on elective procedures and an ASP/mix headwind from rapid adoption of lower‑priced MIS products that pressured top‑line results, though they expect these dynamics to abate in the back half and for growth to return in Q4.

Treace Medical Concepts Stock Up 4.7%

Shares of NASDAQ TMCI traded up $0.09 on Friday, reaching $2.01. 763,851 shares of the company’s stock traded hands, compared to its average volume of 780,081. Treace Medical Concepts has a 12 month low of $1.17 and a 12 month high of $7.78. The business’s 50 day simple moving average is $1.62 and its two-hundred day simple moving average is $2.65. The company has a market cap of $130.21 million, a price-to-earnings ratio of -2.14 and a beta of 1.10. The company has a quick ratio of 3.13, a current ratio of 4.31 and a debt-to-equity ratio of 0.64.

Hedge Funds Weigh In On Treace Medical Concepts

A number of institutional investors and hedge funds have recently made changes to their positions in TMCI. Kotler Kevin bought a new position in shares of Treace Medical Concepts during the fourth quarter valued at approximately $1,162,000. Paradigm Capital Management Inc. NY bought a new position in shares of Treace Medical Concepts during the second quarter valued at approximately $1,577,000. Millennium Management LLC increased its stake in shares of Treace Medical Concepts by 12.7% during the third quarter. Millennium Management LLC now owns 1,710,140 shares of the company’s stock valued at $11,475,000 after purchasing an additional 192,929 shares in the last quarter. Jump Financial LLC bought a new position in shares of Treace Medical Concepts during the fourth quarter valued at approximately $380,000. Finally, Moore Capital Management LP bought a new position in shares of Treace Medical Concepts during the third quarter valued at approximately $990,000. Institutional investors own 84.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on TMCI shares. Lake Street Capital decreased their price target on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Treace Medical Concepts in a research note on Monday, April 20th. Finally, Wall Street Zen raised shares of Treace Medical Concepts from a “strong sell” rating to a “sell” rating in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Treace Medical Concepts currently has an average rating of “Reduce” and an average target price of $4.77.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.